| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Studies |
Division of Endocrinology/Andrology, Hospital Vrije Universiteit (J.M.H.E., H.A., J.A.J.M., L.J.G.G.), Amsterdam; and the Department of Chronic Disease and Environmental Epidemiology, National Institute of Public Health and Environmental Protection (J.C.S.), Bilthoven, The Netherlands
Address all correspondence and requests for reprints to: Dr. H. Asscheman, Division of Endocrinology/Andrology, Hospital Vrije Universiteit, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands.
| Abstract |
|---|
|
|
|---|
We conclude that long term testosterone administration in young, nonobese, female subjects increases the amount of visceral fat. In addition, an increase in weight in this hyperandrogenic state leads to a preferential storage of fat in the visceral depot.
| Introduction |
|---|
|
|
|---|
In the present study, we investigated prospectively the effect of long term testosterone administration on body fat distribution in young, nonobese, female to male transsexuals undergoing sex reassignment to a male status following a standardized regimen (9). This enabled us to study the effect of (exogenous) hyperandrogenicity on the distribution of body fat by quantification of both sc and visceral fat depots in female subjects.
| Subjects and Methods |
|---|
|
|
|---|
Ten young, nonobese, female to male transsexuals (mean age \ SD, 24 \ 6 yr; range, 1633 yr; mean body mass index, 23.0 \ 3.0 kg/m2; range, 18.726.9 kg/m2) participated in the study. They were healthy, as assessed by their medical histories, physical examinations, and laboratory measurements. They were studied before, after 1 yr, and after, on the average, 3.2 \ 0.4 yr of testosterone administration (range, 2.53.8 yr). They were treated with 250 mg testosterone esters (Sustanon 250, Organon, Oss, The Netherlands) every 2 weeks, im, until they were ovariectomized as part of the cross-sex treatment after, on the average, 1.9 \ 0.4 yr. After ovariectomy, they continued testosterone treatment with im injections of 250 mg testosterone esters every 3 weeks. Two subjects switched to 160 mg testosterone undecanoate (Andriol, Organon)/day, orally, during the last year. The study was approved by the ethical review board of the Hospital Vrije Universiteit, and all subjects provided informed consent.
Anthropometry and body fat distribution
Body weight was measured to the nearest 0.1 kg, and height was measured to the nearest 0.1 cm with subjects wearing only underwear. Magnetic resonance (MR) imaging was performed on a whole body scanner with a magnetic field strength of 0.6 Tesla (Teslacon II, Technicare, Solon, OH). An inversion recovery pulse sequence was used with a repetition time of 524 ms, an echo time of 24 ms, and an inversion time of 190 ms. The slice thickness was 10 mm, and the field of view was 410 or 450 mm. Transverse MR images were obtained at the level of the abdomen (lower edge of the umbilicus), the hip (upper margin of the great trochanter), and the thigh (just below the gluteal fold). Three images were taken simultaneously at each body region: one image at the level of the marker, one above, and one below this position, with a gap between the images of 0.25 cm. In all subjects, the same anatomical markers and imaging parameters were used in repeated MR acquisition.
Quantification of sc and visceral fat areas was performed using an image-analyzing computer program (developed by our Department of Biomedical Engineering) (10), based on a seed-growing procedure. After a seed point is placed in a fat depot, this fat depot can be circumscribed by selection of a pixel intensity range. The intensity range is selected for each image separately according to the pixel intensity histogram. The area of the circumscribed fat depot is quantified by converting the number of pixels to square centimeters. Muscle area was calculated from subtracting the areas of sc fat, bone, and connective tissue from the total area on the image below the marker at thigh level. To reduce variability, image analysis was performed by one observer, and the average fat area of three images per level was used in the statistical analysis. Coefficients of variation for intraobserver variability in sc fat area measurements were 2.3% (abdomen), 2.4% (hip), and 2.2% (thigh); that for visceral fat area measurements was 9.8%. Due to a technical error, the digital MR information of four subjects for one measurement occasion was lost. The original MR information on film was available and was redigitalized (Lumiscan 100, Lumisys, Sunnyvale, CA) to quantify the fat depots. To study the variability introduced by the digitalization step, MR data for all subjects were also analyzed using this procedure. No statistical difference was observed between the two measurements, and coefficients of variation appeared to be in the same range, i.e. for sc fat area measurements, between 23%, and for the visceral fat area, 10.7%.
Blood samples
Before and after 1 yr of testosterone administration, blood samples were obtained after an overnight fast. Standardized RIAs were used to measure serum levels of testosterone (Coat-A-Count, Diagnostic Products Corp., Los Angeles, CA) and 17ß-estradiol (Double Antibody, Sorin Biomedica, Saluggia, Italy). Sex hormone-binding globulin was measured using an immunoradiometric assay (Orion Diagnostica, Espoo, Finland).
Statistics
Variables and changes in variables during treatment did not differ statistically from a normal distribution. Baseline variables are expressed as the mean \ SD, and changes in variables during treatment are presented as the mean change from baseline and 95% confidence intervals. Because of the small study population, the paired Wilcoxon signed rank test was used to test the effect of 1 yr and 3 yr testosterone treatments vs. baseline values for the variables studied. The Spearman rank correlation test was used to study correlations between variables. Two-sided P < 0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
|
|
|
| Discussion |
|---|
|
|
|---|
It is not likely that a state of hypoestrogenism after ovariectomy might (partially) explain our findings. Part of the administered testosterone is peripherally aromatized to estradiol. In a study in which we investigated ovariectomized female to male transsexuals receiving similar testosterone dosages, serum estradiol levels were not different from levels in eugonadal women in their early follicular phase (12) and were similar to those in eugonadal men. Thus, after ovariectomy, testosterone administration to our subjects still generated serum estradiol levels in a range comparable to levels in eugonadal women in the follicular phase. Further, the association between weight gain and visceral fat accumulation points in the same direction after 1 yr of testosterone administration as after 3 yr of testosterone administration, indicating that ovariectomy did not lead to a change in this relationship.
A limitation of the present study is the fact that it was not possible to compose a control group of young women with the same degree of variation in weight over 3 yr of follow-up. To our knowledge no detailed long term studies have been performed investigating prospectively the changes in the visceral fat depot in young women. However, cross-sectional studies in young women have shown that fat tissue is mainly located in the sc fat depots and that excess fat is preferentially stored sc, with a rather constant visceral fat depot (3, 4, 13). We, therefore, compared our data with those obtained for quantification of sc and visceral fat areas in 34 Dutch women with a wide range in age and body mass index (13). It appeared in our subjects that the increase in visceral fat area was larger and the change in sc fat area was smaller than expected on the basis of findings in the comparison group, although such a comparison with our study population should be performed with caution.
In an earlier study we found that 4-month administration of similar doses of testosterone to female to male transsexuals (of comparable age) did not increase fasting insulin levels significantly, but did lead to decreased insulin sensitivity (14). This observation, combined with our present results, shows similarities with the findings in women with high endogenous testosterone levels. The latter show both increased abdominal fat depots and insulin resistance. In the subjects of our study, nonobese, endocrine unremarkable, female subjects between the ages of 1633 yr, the primary event leading to abdominal fat accumulation and insulin insensitivity was exogenous hyperandrogenism. This observation might be relevant for determination of the primary event in women with a combination of hyperandrogenism, insulin resistance, and abdominal fat accumulation. Some researchers believe that hyperinsulinemia is the primary event (7). Of note, however, is the fact that in our experiment testosterone levels were far above levels encountered in most spontaneous hyperandrogenic states in women.
These findings in women are dissimilar with some observations in men. Cross-sectional studies in men suggest an inverse association between testosterone levels and abdominal fat distribution (15). Oral testosterone treatment of middle-aged obese men with low normal testosterone levels seemed to reduce visceral fat (16). The oral administration might have been significant for the effects of the testosterone preparation, as in a study comparing the effects of oral anabolic steroids with those of parenteral testosterone treatment (as used in our study), only the oral preparation had this effect, not the parenteral testosterone preparation (17). Further, factors such as age or duration of testosterone exposure may determine the effect of testosterone on visceral fat. The men in the above studies (16, 17) were at least 40 yr of age or older, with a presumed exposure to their endogenous testosterone of some 25 yr.
This study resolves some of the uncertainties with regard to the association between testosterone and visceral fat in women by demonstrating that long term testosterone exposure increases visceral fat in young, nonobese female subjects.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received December 18, 1996.
Revised March 24, 1997.
Accepted March 31, 1997.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Y. Zhang, E. Calvo, C. Martel, V. Luu-The, F. Labrie, and A. Tchernof Response of the adipose tissue transcriptome to dihydrotestosterone in mice Physiol Genomics, November 12, 2008; 35(3): 254 - 261. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Chiolero, D. Faeh, F. Paccaud, and J. Cornuz Consequences of smoking for body weight, body fat distribution, and insulin resistance Am. J. Clinical Nutrition, April 1, 2008; 87(4): 801 - 809. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Gooren, E. J. Giltay, and M. C. Bunck Long-Term Treatment of Transsexuals with Cross-Sex Hormones: Extensive Personal Experience J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 19 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Alexanderson, E. Eriksson, E. Stener-Victorin, T. Lystig, B. Gabrielsson, M. Lonn, and A. Holmang Postnatal Testosterone Exposure Results in Insulin Resistance, Enlarged Mesenteric Adipocytes, and an Atherogenic Lipid Profile in Adult Female Rats: Comparisons with Estradiol and Dihydrotestosterone Endocrinology, November 1, 2007; 148(11): 5369 - 5376. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nader and E. Diamanti-Kandarakis Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis Hum. Reprod., February 1, 2007; 22(2): 317 - 322. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.F. Escobar-Morreale, G. Villuendas, J.I. Botella-Carretero, F. Alvarez-Blasco, R. Sanchon, M. Luque-Ramirez, and J.L. San Millan Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study Hum. Reprod., September 1, 2006; 21(9): 2257 - 2265. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. van Anders and E. Hampson Waist-to-Hip Ratio Is Positively Associated With Bioavailable Testosterone but Negatively Associated With Sexual Desire in Healthy Premenopausal Women Psychosom Med, March 1, 2005; 67(2): 246 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Ong, N. Potau, C. J. Petry, R. Jones, A. R. Ness, J. W. Honour, F. de Zegher, L. Ibanez, and D. B. Dunger Opposing Influences of Prenatal and Postnatal Weight Gain on Adrenarche in Normal Boys and Girls J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2647 - 2651. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ibanez and F. de Zegher Flutamide-Metformin Therapy to Reduce Fat Mass in Hyperinsulinemic Ovarian Hyperandrogenism: Effects in Adolescents and in Women on Third-Generation Oral Contraception J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4720 - 4724. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Moore, A. Wisniewski, and A. Dobs Endocrine Treatment of Transsexual People: A Review of Treatment Regimens, Outcomes, and Adverse Effects J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3467 - 3473. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ibanez, K. K. Ong, N. Mongan, J. Jaaskelainen, M. V. Marcos, I. A. Hughes, F. de Zegher, and D. B. Dunger Androgen Receptor Gene CAG Repeat Polymorphism in the Development of Ovarian Hyperandrogenism J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3333 - 3338. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ibanez, K. Ong, A. Ferrer, R. Amin, D. Dunger, and F. de Zegher Low-Dose Flutamide-Metformin Therapy Reverses Insulin Resistance and Reduces Fat Mass in Nonobese Adolescents with Ovarian Hyperandrogenism J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2600 - 2606. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kilciler, M. Ozata, C. Oktenli, S.Y. Sanisoglu, E. Bolu, N. Bingol, M. Kilciler, I. C. Ozdemir, and M. Kutlu Diurnal Leptin Secretion Is Intact in Male Hypogonadotropic Hypogonadism and Is Not Influenced by Exogenous Gonadotropins J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5023 - 5029. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Anderson, P. G. McTernan, A. H. Barnett, and S. Kumar The Effects of Androgens and Estrogens on Preadipocyte Proliferation in Human Adipose Tissue: Influence of Gender and Site J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 5045 - 5051. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Wajchenberg Subcutaneous and Visceral Adipose Tissue: Their Relation to the Metabolic Syndrome Endocr. Rev., December 1, 2000; 21(6): 697 - 738. [Abstract] [Full Text] |
||||
![]() |
R. Rosmond, Y. C. Chagnon, G. Holm, M. Chagnon, L. Pérusse, K. Lindell, B. Carlsson, C. Bouchard, and P. Björntorp Hypertension in Obesity and the Leptin Receptor Gene Locus J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3126 - 3131. [Abstract] [Full Text] |
||||
![]() |
J. R. Eisner, D. A. Dumesic, J. W. Kemnitz, and D. H. Abbott Timing of Prenatal Androgen Excess Determines Differential Impairment in Insulin Secretion and Action in Adult Female Rhesus Monkeys J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1206 - 1210. [Abstract] [Full Text] |
||||
![]() |
M. N. Dieudonne, R. Pecquery, M. C. Leneveu, and Y. Giudicelli Opposite Effects of Androgens and Estrogens on Adipogenesis in Rat Preadipocytes: Evidence for Sex and Site-Related Specificities and Possible Involvement of Insulin-Like Growth Factor 1 Receptor and Peroxisome Proliferator-Activated Receptor {gamma}2 Endocrinology, February 1, 2000; 141(2): 649 - 656. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rosenbaum and R. L. Leibel Role of Gonadal Steroids in the Sexual Dimorphisms in Body Composition and Circulating Concentrations of Leptin J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1784 - 1789. [Full Text] |
||||
![]() |
J. M. H. Elbers, H. Asscheman, J. C. Seidell, and L. J. G. Gooren Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals Am J Physiol Endocrinol Metab, February 1, 1999; 276(2): E317 - E325. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Giltay, J. M. H. Elbers, L. J. G. Gooren, J. J. Emeis, T. Kooistra, H. Asscheman, and C. D. A. Stehouwer Visceral Fat Accumulation Is an Important Determinant of PAI-1 Levels in Young, Nonobese Men and Women : Modulation by Cross-Sex Hormone Administration Arterioscler. Thromb. Vasc. Biol., November 1, 1998; 18(11): 1716 - 1722. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Miller, C. Corcoran, C. Armstrong, K. Caramelli, E. Anderson, D. Cotton, N. Basgoz, L. Hirschhorn, R. Tuomala, D. Schoenfeld, et al. Transdermal Testosterone Administration in Women with Acquired Immunodeficiency Syndrome Wasting: A Pilot Study J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2717 - 2725. [Abstract] [Full Text] |
||||
![]() |
J. M. H. Elbers, H. Asscheman, J. C. Seidell, M. Frolich, A. E. Meinders, and L. J. G. Gooren Reversal of the Sex Difference in Serum Leptin Levels upon Cross-Sex Hormone Administration in Transsexuals J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3267 - 3270. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |